Ovarian cancer is the second leading gynecologic cancer and, the most deadly, accounting for more than 15,000 deaths annually. Because there is no accurate screening test to detect ovarian cancer, it is typically diagnosed at a late stage when it is more difficult to treat. To improve these outcomes, EIF’s Women’s Cancer Program’s newest initiative focuses on ovarian cancer.

In order to fast-track breakthrough treatments and tests for ovarian cancer, EIF has selected four institutions for their groundbreaking work in ovarian cancer research and treatment, including: Cedars-Sinai Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute; The University of Texas M.D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Led by Dr. Beth Karlan, Director of the Cedars-Sinai Women's Cancer Research Institute, this women's cancer initiative represents a collaborative, multi-site undertaking designed to advance treatment of ovarian cancer through molecular profiling, biomarker discovery and targeted therapy development.

To learn more about what EIF is doing for ovarian cancer through the Callaway Golf Foundation’s Women’s Cancer Initiative, click here.

Click here to learn more about individual grantees.